Cardiogenomics Market Report 2025

The cardiogenomics market size has grown rapidly in recent years. It will grow from $1.5 billion in 2024 to $1.74 billion in 2025 at a compound annual growth rate (CAGR) of 15.8%. The growth in the historic period can be attributed to the expanding use of polygenic risk scores in cardiac care, increasing investments in genomic research and development, higher government and private funding for cardiovascular genomics, growing interest in preventive cardiology informed by genetic insights, and greater focus on population-scale genomic studies.

The cardiogenomics market size is expected to see rapid growth in the next few years. It will grow to $3.1 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to rising demand for personalized medicine, increasing prevalence of cardiovascular diseases, higher adoption of genetic testing for early risk detection, greater awareness of precision medicine approaches, and expanded availability of direct-to-consumer genetic testing services. Key trends in the forecast period include technological innovations in sequencing enabling precise cardiac analysis, integration of genomics with health records supporting personalized care, improvements in polygenic risk scoring for early disease prediction, advancements in bioinformatics accelerating genomic data interpretation, and platforms supporting high-throughput genetic testing.

Rising demand for personalized medicine is expected to drive growth in the cardiogenomics market. Personalized medicine customizes prevention, diagnosis, and treatment according to an individual’s genetic makeup, environment, and lifestyle. Advances in genomics have increased personalized medicine by providing greater insight into genetic variations, enabling more precise and targeted treatments that enhance patient outcomes and reduce trial-and-error approaches. Cardiogenomics supports personalized medicine by using genetic information to tailor the prevention, diagnosis, and treatment of cardiovascular diseases to each person’s unique genetic profile. For example, in February 2024, the Personalized Medicine Coalition, a US nonprofit, reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. The 2023 approvals also included seven cancer drugs and three treatments for other conditions. This rising demand for personalized medicine is fueling the growth of the cardiogenomics market.

Key companies in the cardiogenomics market are developing innovative solutions such as oncogenomics to improve early detection and personalized treatment of cancers related to cardiovascular health. Oncogenomics studies cancer-associated genes and mutations to better understand cancer progression and develop targeted therapies and personalized treatment options. For instance, in April 2025, Fortis Healthcare Ltd., an India-based healthcare provider, opened the Fortis Institute of Genomic Medicine to advance genetic research and personalized care. The institute enhances patient treatment by enabling early disease detection, accurate diagnosis, and personalized therapies across fields including oncology, cardiology, and neurology. It supports targeted treatments, improves patient outcomes, and promotes preventive care for hereditary conditions. The institute’s goal is to advance precision medicine through a multidisciplinary team and innovative technologies, making healthcare more tailored and effective for Indian patients.

In March 2025, Tempus AI Inc., a US-based technology firm, acquired Ambry Genetics Corporation for an undisclosed sum. This acquisition aims to enhance Tempus AI’s precision medicine offerings by combining genetic testing with AI-driven data analysis to improve patient outcomes and provide personalized care across multiple diseases. Ambry Genetics Corporation is a US genetic testing and precision medicine company that provides cardiogenomics services.

Major players in the cardiogenomics market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., ARUP Laboratories, BGI Genomics Co. Ltd., Invitae Corporation, GeneDx Inc., Helix OpCo LLC, SOPHiA GENETICS SA, Baylor Genetics, Blueprint Genetics, Novogenia GmbH, Veritas Genetics, Dante Genomics, Gene by Gene Ltd., GENinCode Plc., UAB Cardiogenomics Clinic.

North America was the largest region in the cardiogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiogenomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Cardiogenomics is the study of how an individual’s genetic variations affect the risk, onset, and progression of cardiovascular diseases. It is essential for enabling personalized prevention, precise diagnosis, and targeted treatment strategies to improve heart health outcomes.

The primary product types in cardiogenomics are testing kits, reagents, instruments, software, and services. Testing kits are packaged tools and consumables designed to conduct specific genetic tests. The technologies used include next-generation sequencing, polymerase chain reaction, microarrays, and others. These products are applied in areas such as congenital heart diseases, cardiomyopathies, arrhythmias, coronary artery disease, and others, and serve end-users including hospitals and clinics, diagnostic laboratories, research institutions, and others.

The cardiogenomics market research report is one of a series of new reports that provides cardiogenomics market statistics, including cardiogenomics industry global market size, regional shares, competitors with a cardiogenomics market share, detailed cardiogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the cardiogenomics industry. This cardiogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiogenomics market consists of revenues earned by entities by providing services such as genetic testing and screening, risk assessment and prediction, and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiogenomics market also includes sales of cardiogenomic testing panels, genetic testing panels, and direct-to-consumer (DTC) genetic tests. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.